1. Introduction {#s1}
===============

The definitions of the five different clinical types of acute myocardial infarction (AMI) have recently been updated:[@b1] type-1 AMI is caused by an acute atherothrombotic coronary event; type-2 AMI is a more heterogeneous entity, where a condition other than coronary artery disease (CAD) contributes to an acute imbalance between oxygen supply (e.g., hypoxemia, anemia, hypotension) and demand (e.g., tachycardia, hypertension). In critically ill patients, or in patients undergoing major (non-cardiac) surgery, elevated values of cardiac biomarkers may appear, due to the direct toxic effects of endogenous or exogenous high circulating catecholamine levels. Also coronary vasospasm and/or endothelial dysfunction have the potential to cause type-2 AMI.

Evidence-based treatment recommendations for type-1 AMI are clearly established, however for type-2 AMI these recommendations are lacking. Moreover, treatment strategies in clinical practice in these patients are frequently limited because of a higher co-morbidity of this population. A recent study showed that patients with type-2 AMI are more frequently managed non-invasively and received less frequently cardio-protective drugs.[@b2],[@b3] Also, there are controversial data about the prognosis of these patients. While some authors have shown this population is strongly associated with a high mortality rate,[@b4],[@b5] other studies have demonstrated that mortality compared with those patients with type-1 AMI is similar after multivariate adjustment, probably reflecting the poor clinical profile of this group compared with type-1 AMI patients.[@b3] Thus, the aim of the present study was to compare the patient clinical profiles, treatment strategies, mortality and other clinical outcomes such as recurrent MI, stroke or major bleeding (MB) complications between patients with type-2 and type-1 AMI.

2. Methods {#s2}
==========

The present study is a retrospective analysis of a tertiary university hospital registry. Between January 1, 2012 and September 30, 2013, 824 consecutive patients admitted to the cardiology division with a diagnosis of type-1 or type-2 AMI were included. Patients were classified as having type-1 or type-2 AMI according to the third universal MI definition,[@b1] and for each case a consensus reached by three cardiologists was needed. Two of these three cardiologists assigned the cause of type-2 AMI. For patients with more than one potential cause, these two doctors selected the initial or fundamental cause. A third cardiologist was consulted, if there was a difference of opinion, to get a consensus. During the index hospitalization, data on demographic and clinical characteristics, medication as well as laboratory, ECG, echocardiography, angiography parameters and clinical complications were collected in detail. The study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of the University Hospital Virgen de la Arrixaca-University of Murcia.

Patients were followed-up from admission date to occurrence of death or until day 365 using a standardized protocol that included outpatient clinic attendance, telephone contact and review of the medical notes. Six patients were lost to follow-up. The end-point of the study was the occurrence of all-cause mortality, non-fatal MI, stroke and MB complications. Information on deaths was ascertained from available medical records and death certificates. MI was defined as detection of rise in cardiac biomarkers of necrosis with at least one measurement above the 99^th^ percentile upper reference limit, together with evidence of myocardial ischemia with at least one of the following: electrocardiographic changes indicative of new ischemia (new ST-T changes or new left bundle branch block), new pathological Q waves in at least two contiguous leads, imaging evidence of new loss of viable myocardium or new wall motion abnormality.[@b1],[@b6],[@b7] Stroke was defined as any clinical manifestation of acute cerebral ischemia or hemorrhage that was ascertained by objective diagnostic/imaging testing.[@b8] MB was defined according to the Bleeding Academic Research Consortium Definition criteria as bleeding types 3--5.[@b9]

Categorical variables are presented as frequency values and compared by *χ*^2^-tests. Continuous variables are presented as mean ± SD or as medians and IQRs. Differences in continuous variables were evaluated using independent samples *t*-tests and Mann--Whitney tests, as appropriate. Hazard ratios (HRs) were assessed from Cox regression models. The independent effect of AMI type on clinical outcomes was calculated using a Cox multivariate regression analysis. The covariates were chosen based on clinical considerations and confounders known from risk-stratification models. Linearity assumption was tested using Martingale residuals. Log-cumulative hazard plots, time-dependent covariates, and Schoenfeld residuals were used to evaluate adherence of the proportional hazard assumptions of the Cox model. All *P*-values (2 tailed) \< 0.05 were accepted as statistically significant. Given that this is a retrospective cohort study, it was necessary to achieve comparability of both groups (type-1 and type-2 AMI) with regard to potential confounding variables. This was accomplished using propensity score matching. Variables used to compute the propensity score were those which showed differences between both AMI types and those related with the clinical endpoints. If two variables were related (for example, serum creatinine and estimated glomerular filtration rate), we only selected one of them according to criteria of reproducibility, objectivity and less missing value. Finally, medications at discharge were not used to compute the propensity score because a significant reduction in sample size generated by excluding patients with in-hospital death. We used generalized boosted models attempting a 1: 1 ratio, with no interactions included. Balance between both groups was assessed by unweighted standardized mean differences, variance ratios, histograms and jitter plots of propensity score distribution and visual inspection of QQ plots. HRs calculated in matched population with multivariate analysis were adjusted by those variables not properly balanced after propensity score matching. Statistical analysis was performed using statistical software SPSS 15.0 for Windows.

3. Results {#s3}
==========

3.1. Clinical characteristics of the study population {#s3a}
-----------------------------------------------------

The study population consisted of 824 patients. Of them, 707 (86%) had type-1 AMI and 117 (14%) had type-2 AMI. The most common causes of type-2 AMI were tachyarrhythmias (36.7%), aortic stenosis (14.5%) and heart failure (13.7%). [Tables 1](#jgc-13-01-015-t01){ref-type="table"}--[4](#jgc-13-01-015-t04){ref-type="table"} show patients characteristics before and after propensity score matching. Compared with patients with type-1 AMI, those with type-2 were older, more frequently women and had higher co-morbidities such as hypertension, heart failure, impaired renal function, anaemia, atrial fibrillation and malignancy ([Table 1](#jgc-13-01-015-t01){ref-type="table"}). After matching, type-1 and type-2 AMI patients were similar with regards to almost all baseline covariates introduced in the propensity matching analysis ([Table 4](#jgc-13-01-015-t04){ref-type="table"}). Our propensity score matching reduced standardized differences for almost all observed covariates below 20% in absolute value, demonstrating substantial improvement in covariate balance across the AMI type groups ([Figure 1](#jgc-13-01-015-g001){ref-type="fig"}).

###### Study population clinical characteristics as a function of acute myocardial infarction type.

  Variables                      Whole population      *P*     
  ----------------------------- ------------------ ----------- ----------
  Age, yrs                           68 ± 13         72 ± 12    \< 0.001
  Male                              539 (76%)       61 (52%)    \< 0.001
  Diabetes mellitus                 336 (48%)       52 (44%)     0.536
  Hypertension                      522 (74%)       103 (88%)    0.001
  Hyperlipidemia                    530 (75%)       89 (76%)     0.798
  Current smoking                   232 (33%)       23 (20%)    \< 0.001
  Previous STEMI                    101 (14%)       19 (16%)     0.587
  Previous NSTE-ACS                 160 (22%)       40 (34%)     0.007
  Previous PCI                      196 (28%)       40 (34%)     0.152
  Previous CABG                      31 (4%)        12 (10%)     0.008
  Chronic heart failure              42 (6%)        21 (18%)    \< 0.001
  Previous stroke                    81 (12%)       20 (17%)     0.085
  Peripheral artery disease          57 (8%)         11 (9%)     0.626
  Atrial fibrillation/flutter       103 (15%)       51 (44%)    \< 0.001
  Malignancy                         48 (7%)        15 (13%)     0.023
  COPD                               71 (10%)       17 (15%)     0.145

Data are expressed as mean ± SD or *n* (%). CABG: coronary artery bypass; COPD: chronic obstructive pulmonary disease; NSTE-ACS: non-ST-segment acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention.

3.2. Symptoms, signs and complementary studies {#s3b}
----------------------------------------------

As shown in [Table 2](#jgc-13-01-015-t02){ref-type="table"}, the main symptom of presentation differed from type-2 to type-1 AMI. While dyspnoea was more common in type-2 AMI, chest pain was more frequent in patients with type-1 AMI. At hospital admission, patients with type-2 AMI had higher heart rate than patients with type-1 AMI. Moreover, pulmonary crackles, legs oedema and cardiomegaly on chest X-ray were more frequently in type-2 AMI patients. In patients with type-2 AMI, the admission ECG showed ST-segment depression and transient ST-segment elevation more often than in patients with type-1 AMI ([Table 2](#jgc-13-01-015-t02){ref-type="table"}). However, persistent ST-segment elevation and pathological Q waves were less frequent in patients with type-2 AMI. Laboratory analyses showed that patients with type-2 AMI had lower estimated glomerular filtration rate, haemoglobin and higher sensitivity troponin T concentrations. In addition, these patients also had more often significant aortic stenosis and mitral regurgitation, but similar left ventricular ejection fraction on echocardiogram ([Table 2](#jgc-13-01-015-t02){ref-type="table"}).
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3.3. Management {#s3c}
---------------

Reperfusion strategies and invasive treatment was less common in patients with type-2 AMI than those with type-1 AMI ([Table 3](#jgc-13-01-015-t03){ref-type="table"}). Moreover, among patients who underwent coronary angiography, normal coronary arteries or non-obstructive CAD (\< 50% stenosis) were more common in type-2 than in type-1 AMI (67% *vs*. 9%, *P* \< 0.001). During hospitalization period, patients with type-2 AMI underwent invasive coronary angiography were less frequently and less often revascularized than patients with type-1 AMI ([Table 3](#jgc-13-01-015-t03){ref-type="table"}). As expected, the use of thrombolytic agents and glycoprotein IIB/IIIA inhibitors were less frequent in type-2 AMI as compared with type-1 AMI. At hospital discharge, cardio-protective medications such as β-blockers, ACE inhibitors and statins were less often prescribed to type-2 AMI patients. Antiplatelet drugs were also less often prescribed, while anticoagulants and diuretics were more often prescribed to patients with type-2 AMI. By contrast, use of anti-aldosterone antagonists and angiotensin II receptor blockers did not differ between the groups ([Table 3](#jgc-13-01-015-t03){ref-type="table"}).

3.4. Prognosis {#s3d}
--------------

In both whole population and propensity matched cohort, there is a lower incidence of in-hospital MI in patients with type-2 versus those with type-1 AMI (whole population: 0% *vs*. 4%, *P* = 0.038 and matched population: 0% vs. 6%, *P* = 0.029). However, the incidence of all other in-hospital complications was comparable in both groups ([Table 5](#jgc-13-01-015-t05){ref-type="table"}).

###### Symptoms, signs and complementary studies findings as a function of acute myocardial infarction type.

  Variables                          Whole population        *P*        
  --------------------------------- ------------------ ---------------- ----------
  Symptoms and signs                                                    
   Chest pain                           618 (87%)          87 (74%)      \< 0.001
   Dyspnea                               38 (6%)           22 (19%)      \< 0.001
   Other symptoms                        51 (7%)            8 (7%)        0.987
   Cardiac arrest                        19 (3%)            2 (2%)        0.755
   SBP, mmHg                             134 ± 29          135 ± 31       0.693
   DBP, mmHg                             73 ± 16           72 ± 17        0.532
   Heart rate, beats/min                 80 ± 36           102 ± 36      \< 0.001
   Pulmonary crackles                   152 (22%)          40 (34%)       0.003
   S3                                    22 (3%)            6 (5%)        0.266
   Legs edema                            33 (5%)           13 (11%)       0.005
  Chest X-ray                                                           
   Cardiomegaly                         148 (22%)          41 (36%)       0.001
   Pulmonary congestion                 116 (17%)          25 (22%)       0.193
  Admission ECG findings                                                
   Atrial fibrillation/flutter           49 (7%)           32 (27%)      \< 0.001
   Left bundle branch block              35 (5%)           10 (9%)        0.214
   Q waves                              156 (22%)          12 (10%)       0.006
   ST-segment elevation                 225 (32%)          1 (0.9%)      \< 0.001
   Transient ST-segment elevation        19 (3%)            9 (8%)        0.011
   ST-segment depression                152 (22%)          35 (30%)       0.044
   Symmetric negative T waves           100 (14%)           9 (8%)        0.056
  Laboratory parameters                                                 
   Glucose, mg/dL                        168 ± 87          158 ± 93       0.230
   Serum creatinine, mg/dL              1.1 ± 0.5         1.2 ± 0.6       0.034
   eGFR, mL/min per 1.732 m^2^           80 ± 36           63 ± 28       \< 0.001
   Hemoglobin, g/dL                     13.8 ± 1.9        12.5 ± 2.1     \< 0.001
   Leucocytes, 10^3^/µL                 10.4 ± 4.7        9.5 ± 4.4       0.042
   hs-troponin T, ng/L                70 \[26--283\]    36 \[22--131\]   \< 0.001
  Echocardiogram findings                                               
   LVEF, %                               54 ± 13           56 ± 15        0.172
  Moderate/severe valvulopathy                                          
   Aortic stenosis                       66 (5%)           27 (24%)      \< 0.001
   Aortic insufficiency                  23 (3%)            8 (7%)        0.071
   Mitral regurgitation                  67 (10%)          23 (20%)       0.001
   Tricuspid regurgitation               21 (3%)            7 (6%)        0.106
   Pericardial effusion                  20 (3%)            2 (2%)        0.757

Data are expressed as mean ± SD, median \[interquartile range\] or n (%). DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; SBP: systolic blood pressure.

Patients with type-2 AMI had significantly higher 1-year mortality compared to patients with type-1 AMI (23.3% *vs*. 14.4%, *P* = 0.02) ([Figure 2](#jgc-13-01-015-g002){ref-type="fig"}). By contrast, both type-2 AMI and type-1 AMI had similar rate of non-fatal MI (9.8% *vs*. 10.3%, *P* = 0.87), stroke (3% *vs*. 0.9%, *P* = 0.35) and MB complications (5.7% *vs*. 7.8%, *P* = 0.39) ([Figure 2](#jgc-13-01-015-g002){ref-type="fig"}). In univariate Cox regression analysis ([Table 6](#jgc-13-01-015-t06){ref-type="table"}), type-2 AMI was associated with a higher mortality risk (HR: 1.75, 95% CI: 1.14--2.68; *P* = 0.001), but this association did not remain significant after multivariable adjustment (*P* = 0.785). Furthermore, we did not find type-2 AMI to be associated with other clinical outcomes neither using univariate nor multivariate Cox regression analyses ([Table 6](#jgc-13-01-015-t06){ref-type="table"}). As shown in [Table 6](#jgc-13-01-015-t06){ref-type="table"}, there is no difference in events rate in analysis after propensity score matching.

###### Study population management as a function of acute myocardial infarction type.

  Variables                            Whole population     *P*     
  ----------------------------------- ------------------ ---------- ----------
  In-hospital procedures                                            
   Coronary angiography                   622 (88%)       46 (39%)   \< 0.001
   PCI                                    486 (69%)       11 (9%)    \< 0.001
   Drug eluting stent                     390 (55%)        7 (6%)    \< 0.001
   CABG                                    28 (4%)         0 (0%)     0.024
   Thrombolytic                            28 (4%)         0 (0%)     0.024
   Glycoprotein IIB/IIIA inhibitors       111 (16%)        0 (0%)    \< 0.001
  Medications at discharge\*                                        
   β-blocker                              614 (93%)       86 (78%)   \< 0.001
   ACEI                                   438 (66%)       53 (48%)   \< 0.001
   Angiotensin receptor blockers          160 (24%)       35 (32%)    0.095
   Antialdosterone antagonist             131 (20%)       22 (20%)    0.998
   Diuretic                               230 (35%)       70 (63%)   \< 0.001
   Statins                                648 (96%)       92 (83%)   \< 0.001
   Aspirin                                647 (97%)       72 (65%)   \< 0.001
   Other antiplatelet                     621 (94%)       46 (41%)   \< 0.001
   Oral anticoagulant                      89 (13%)       44 (40%)   \< 0.001

Data are expressed as *n* (%). ACEI: angiotesin converter enzyme inhibitor; CABG: coronary artery bypass; PCI: percutaneous coronary intervention. \*Referred to patients alive at discharge (type 1, *n* = 666; type 2, *n* = 111)

4. Discussion {#s4}
=============

In the present study, we described clinical characteristics, management and prognosis of a consecutive cohort of patients with type-2 AMI in comparison with type-1. Despite the important differences in baseline characteristics, clinical presentation and treatment strategy between the two groups, the 1-year adjusted mortality was similar. Moreover, we showed that the incidence of in-hospital complications and 1-year ischemic or hemorrhagic events was similar in type-1 and type-2 AMI. Also, in our propensity score matched study, we did not find differences with respect to the incidence of 1-year events in both groups.

###### Characteristics of patients as a function of acute myocardial infarction type after propensity score matching.

  Variables                                 Matched population   Absolute standardized differences   Variance ratio   *P*   
  ---------------------------------------- -------------------- ----------------------------------- ---------------- ------ -------
  Age, yrs                                        74 ± 1                      71 ± 12                     19.8        1.11   0.138
  Sex, male                                      55 (56%)                     54 (55)                     2.1         1.00   0.886
  Diabetes mellitus                              57 (58%)                     44 (45)                     26.5        1.02   0.063
  Hypertension                                   83 (85%)                     88 (90)                     16.8        0.71   0.284
  Current smoking                                43 (44%)                     40 (41)                     6.2         0.98   0.665
  Previous NSTE-ACS                              42 (43%)                     35 (36)                     14.8        0.94   0.306
  Chronic heart failure                          15 (15%)                     17 (17)                     5.4         1.11   0.699
  Previous stroke                                16 (16%)                     18 (18)                     5.24        1.09   0.706
  Peripheral artery disease                      13 (13%)                     10 (10)                     10.1        0.79   0.506
  Atrial fibrillation/flutter                    36 (37%)                     39 (40)                     6.2         1.03   0.659
  Malignancy                                     11 (11%)                     13 (13)                     5.9         1.15   0.663
  COPD                                           11 (11%)                     13 (13)                     5.9         1.15   0.663
  Cardiac arrest                                  3 (3%)                       2 (2)                      7.2         0.67   1.000
  Killip ≥ 2                                     68 (69%)                     63 (64)                     10.6        1.08   0.448
  SBP, mmHg                                      130 ± 29                    138 ± 32                     25.6        1.18   0.062
  Heart rate, beats/min                          90 ± 29                      95 ± 33                     16.4        1.36   0.338
  eGFR, mL/min per 1.732 m^2^                    62 ± 24                      62 ± 24                     5.4         1.03   0.868
  Hemoglobin, g/dL                              12.6 ± 2.0                  12.6 ± 2.1                    2.1         1.13   0.999
  hs-troponin T, ng/L                         49 \[24--191\]              34 \[20--126\]                  4.9         1.01   0.267
  LVEF, %                                       54% ± 15%                    55% ± 15%                    9.1         0.94   0.566
  Aortic stenosis (moderate/severe)              29 (30%)                    22 (22%)                     17.0        0.84   0.254
  Mitral regurgitation (moderate/severe)         19 (19%)                    19 (19%)                      0           1     1.000

Data are expressed as mean ± SD, median \[interqueartile range\] or*n* (%). CABG: coronary artery bypass; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; NSTE-ACS: non-ST-segment acute coronary syndrome; SBP: systolic blood pressure.

###### In hospital complications as a function of acute myocardial infarction type.

  Complications                          Whole population   Matched population                              
  ------------------------------------- ------------------ -------------------- ------- ---------- -------- -------
  Use of inotropic agents                    62 (9%)              8 (7%)         0.488    9 (9%)    5 (5%)   0.267
  Intra-aortic balloon pump                   8 (1%)                0            0.248    1 (1%)      0      1.000
  Non-invasive mechanical ventilation        47 (7%)              6 (5%)         0.535   11 (11%)   5 (5%)   0.118
  Invasive mechanical ventilation            48 (7%)              4 (3%)         0.165    6 (6%)    4 (4%)   0.516
  Haemodialysis and/or hemofiltration        4 (0.6%)            1 (0.9%)        0.709      0         0       \-
  Ventricular thrombus                       14 (2%)             1 (0.9%)        0.399      0       1 (1%)   1.000
  Vascular access complications               8 (1%)                0            0.609    2 (2%)      0      0.497
  Ventricular arrhythmias                    39 (6%)              4 (4%)         0.410    7 (7%)    3 (3%)   0.145
  Atrial fibrillation                        29 (4%)              5 (4%)         0.807    4 (4%)    3 (3%)   1.000
  High degree atrioventricular block         28 (4%)              4 (3%)         1.000    4 (4%)    4 (4%)   1.000
  Death                                      41 (6%)              6 (5%)         0.772    8 (8%)    4 (4%)   0.233
  Myocardial infarction                      25 (4%)                0            0.038    6 (6%)      0      0.029
  Stent thrombosis                           6 (0.8%)               0            0.602      0         0       \-
  Stroke                                      7 (1%)                0            0.623    1 (1%)      0      1.000
  Major bleeding                             18 (3%)              3 (3%)         1.000    5 (5%)    2 (2%)   0.445

Data are expressed as *n* (%).
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The third Universal Definition of MI consensus document defines type-2 AMI in instances in which a supply/demand imbalance leads to myocardial injury with necrosis that is not caused by acute coronary syndrome, including arrhythmias, aortic dissection, severe aortic valve disease, hypertrophic cardiomyopathy, shock, respiratory failure, severe anemia, hypertension with or without left ventricular hypertrophy, coronary spasm, coronary embolism or vasculitis, and coronary endothelial dysfunction without CAD.[@b1] In our study, the most common cause of all was tachycardia (36.7%), which represents a similar percentage to that reported in the literature,[@b10] and the ratio type-2/type-1 AMI was 16.5%. Also, the other main causes were similar (heart failure, aortic stenosis, anaemia/bleeding), with a range between 5% and 15%, although in our cohort coronary vasospasm was determined in a higher percentage of patients.[@b10] Previously[@b11] reported global incidence of type-2 AMI varies from 1.6% to 29.6%.[@b11]--[@b13] This wide range reflects the lack of clear and objective diagnostic criteria, where it is difficult to differentiate type-1 from type-2 AMI and also type-2 AMI from myocardial injury of multi-factorial genesis.[@b14] Saaby, *et al*.[@b13] have proposed specific criteria for type-2 AMI, in order to avoid the implicit subjectivity in the clinical diagnosis. However, their application is difficult because of multifactorial nature of the pathophysiologic mechanism of ischemia in these patients.

Considering clinical characteristics of our patients with type-2 AMI compared to type-1, we noted that they did not significantly differ from those showed in other reports.[@b2],[@b10],[@b15] Thus, patients with type-2 AMI were more often women, older and had a higher prevalence of cardiovascular risk factors or co-morbidities, such as hypertension, heart failure, impaired renal function, anaemia, aortic stenosis, atrial fibrillation and malignancy. Prevalence of peripheral artery disease and chronic obstructive pulmonary disease was similar between both groups, although other authors with larger samples have indeed reported differences.[@b2],[@b15] However, little information exists about the clinical presentation of these patients,[@b15] which more frequently presented with dyspnea at admission, with higher heart rate and with more physical examination and radiographic signs of heart failure.

###### Cox regression risk analysis of type-2 acute myocardial infarction for prediction of 1-year clinical events.

  Events                              HR      95% CI        *P*      HR      95% CI        *P*
  --------------------------------- ------ ------------- --------- ------ ------------ -----------
  Death                                                                                
   Unadjusted HR                     1.75   1.14--2.68     0.001    0.84   0.46--1.53     0.569
   Adjusted HR                       0.88   0.50--1.53    0.785\*   0.88   0.48--1.63   0.692\*\*
  Non-fatal myocardial infarction                                                      
   Unadjusted HR                     0.76   0.41--1.41     0.376    1.20   0.52--2.78     0.667
   Adjusted HR                       2.12   0.90--5.28    0.196\*   1.38   0.59--3.22   0.463\*\*
  Stroke                                                                               
   Unadjusted HR                     2.64   0.35--19.61    0.348    0.25   0.3--2.21      0.210
   Adjusted HR                       0.15   0.02--1.50    0.106\*   0.24   0.1--2.18    0.203\*\*
  Major bleeding                                                                       
   Unadjusted HR                     0.61   0.28--1.27     0.176    0.83   0.29--2.28     0.710
   Adjusted HR                       1.17   0.41--3.38    0.768\*   0.89   0.32--2.51   0.825\*\*

\*HRs calculated in total population with multivariate analysis adjusted by age, diabetes mellitus, previous NSTE-ACS, chronic heart failure, atrial fibrillation, previous stroke, peripheral artery disease, malignancy, Killip class, heart rate, SBP, eGFR, hemoglobin, hs-troponin T and LVEF; \*\*HRs calculated in matched population with multivariate analysis adjusted by diabetes mellitus and SBP. eGFR: estimated glomerular filtration rate; HR: harzad ratio; LVEF: left ventricular ejection fraction; NSTE-ACS: non-ST-segment acute coronary syndrome; SBP: systolic blood pressure; STEMI: ST-segment elevation myocardial infarction.

The differences in ECG were also noteworthy. Type-2 AMI patients presented more frequently with ST-segment depression and rarely with persistent elevation. This is consistent with data from other previous studies.[@b2],[@b10] Non-ST-segment elevation MI and ST-segment elevation MI terms may be used with caution in patients with type-2 AMI because they may confuse the healthcare community, who has associated these terms with plaque rupture and all its attendant therapies. Globally in our study, as in previous works,[@b2] patients with type-2 AMI were less likely to undergo coronary angiography or percutaneous coronary angioplasty or to take dual antiplatelet therapy than patients with type-1. The reason for this discrepancy is probably multifactorial. First, these patients have more co-morbidities and their physicians may tend to use more conservative strategies and avoid aggressive treatments. Second, the impact of antithrombotic and/or antiplatelet therapies, as well as the role of reperfusion in patients without plaque rupture are uncertain and might be detrimental or contraindicated in many cases, e.g., in a patient with type-2 AMI in the setting of severe anemia due to an acute gastrointestinal hemorrhage. And finally, the older patients with type-2 AMI may have been less likely to agree to undergo invasive procedures or to take multiple medications.[@b16],[@b17] On the other hand, patients with type-2 AMI less often received secondary preventive treatment such as β-blockers, statins or angiotensin-converting-enzyme inhibitors and more commonly receive specific treatment for concomitant diseases, as anticoagulants for atrial fibrillation or diuretics for heart failure. All these discrepancies in management of both groups of patients are common in studies published before and are due to the absence of guidelines addressing the acute or long-term treatment of this entity.[@b11] So, there is an urgent need for evidence-based diagnostic and therapeutic strategies, primarily randomized, controlled clinical trials.

Finally, we have analyzed in detail the prognosis of these patients. We did not find differences regarding in-hospital complications and 1-year incidence of ischemic (non-fatal MI, stent thrombosis or stroke) or MB events. To our knowledge, only it has been published a study that included in-hospital complications,[@b15] where most of these complications were more common of patients with type-1 compared to patients with type-2 AMI. However, the absence of multivariate analysis in this study makes it difficult to identify predictors for and risk-stratification of type-2. Therefore we analyzed the prognosis of these patients showing the importance of each of these predictors. Moreover, in univariate analysis, 1-year mortality was higher in type-2 AMI patients but after adjustment for confounding factors this difference did not achieve statistical significance. Previous studies have shown contradictory results regarding long-term mortality. In the Swedish study of Baron *et al*.,[@b10] the crude 1-year mortality was higher in type-2 AMI than type-1 but after adjustment background characteristics, treatments and clustering by treating hospitals, the difference was attenuated and did not reach statistical significance, reflecting that the higher crude mortality in type-2 AMI may be caused by factors other than the type of AMI itself. However, Saaby, *et al*.[@b2] reported that type-2 AMI was a significant predictor of an adverse outcome using multivariable regression analysis. This controversy may be probably explained by the heterogeneity of the patients included in these studies due to the subjectivity of the diagnostic criteria for type-2 AMI and by the different diagnostic methods used (only the Danish study, like us, used a high sensitivity troponin assay for all patients).[@b18] Also, unlike previous studies, we used propensity score matching to control for several potential confounding variables unevenly distributed between groups. The "negative" results in our study need to be interpreted in the context of whether these might be type II errors. So, further studies are needed to clarify the diagnosis, treatment and prognosis of patients with type-2 AMI.

There are some limitations in the present study that need to be considered. It is small and reflective of the experience of one hospital in Spain. Only patients admitted to our unit, which is equipped to perform coronary angiography and coronary revascularizations, were included; the applicability of the present results should therefore be viewed with caution in centers with other types of populations and medical facilities, and should be considered as hypothesis generating. However, single-center studies offer the advantage of evaluating homogeneous populations and care processes, unlike multicenter studies, which often differ in the availability of their logistical resources and management habits. The small sample size is a critical limitation that makes it difficult to draw firm conclusions. A study with a larger sample size and more registered events would provide more power. Nonetheless, the demographics and outcomes of our study subjects are comparable to other type-2 AMI. Complete cardiac examinations were not performed in all patients. Thus, diagnostic procedures and supplementary blood sampling were done at the discretion of the treating physicians. The lower rate of coronary angiography in type-2 AMI may, in part, reflect verification bias of an unexpected finding of culprit lesion, which can lead to reclassification to type-1 AMI. As the patients with type-2 AMI were older and had more comorbidities, they might more likely have been treated in clinical departments other than cardiac care units and, therefore, not registered in our registry. Thus, the true incidence of type-2 AMI might be underestimated in the present study. Finally, when analyzing a single baseline variable, propensity score matching in one of the most robust ways of approaching observational data in order to reduce confounding and assess possible causality. In this study, acceptable balance between type-1 and type-2 AMI groups was achieved. However, regardless of rigorous statistical efforts, residual confounding almost certainly exists.

In conclusion, in this real-life population, type-2 AMI were predominantly women and had more comorbidities compared with type-1. Although invasive treatment strategies and cardio-protective medications were less used in type-2 AMI, the 1-year clinical outcomes were similar.
